DexCom Inc (MIL:1DXCM) Stock Price, Trades & News

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	1.74
Equity-to-Asset	0.45
Debt-to-Equity	0.47
Debt-to-EBITDA	0.94
Interest Coverage	61.88
Piotroski F-Score	9/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	6.61	Distress Grey Safe
Beneish M-Score	-3.16	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	19.1
	3-Year EBITDA Growth Rate	36.3
	3-Year EPS without NRI Growth Rate	33.9
	3-Year FCF Growth Rate	55
	3-Year Book Growth Rate	8.9
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	20.4
	Future 3-5Y Total Revenue Growth Rate Estimate	11.77

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	18.15
	9-Day RSI	30.7
	14-Day RSI	41.71
	3-1 Month Momentum %	18.6
	6-1 Month Momentum %	12.61
	12-1 Month Momentum %	-15.32

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.95
	Quick Ratio	1.64
	Cash Ratio	1.09
	Days Inventory	119.48
	Days Sales Outstanding	89.67
	Days Payable	82.42

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	0.1
	Shareholder Yield %	2.18

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	61.5
	Operating Margin %	21.45
	Net Margin %	19.31
	EBITDA Margin %	30.7
	FCF Margin %	29.64
	OCF Margin %	36.97
	ROE %	35.06
	ROA %	13.46
	ROIC %	25.94
	3-Year ROIIC %	-195.89
	ROC (Joel Greenblatt) %	78.61
	ROCE %	29.76
	Years of Profitability over Past 10-Year	7
	Moat Score	7
	Tariff Resilience Score	5

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	29.43
	Forward PE Ratio	27.81
	PE Ratio without NRI	29.55
	Shiller PE Ratio	84.38
	Price-to-Owner-Earnings	18.89
	PEG Ratio	0.94
	PS Ratio	5.74
	PB Ratio	8.99
	Price-to-Tangible-Book	9.32
	Price-to-Free-Cash-Flow	19.36
	Price-to-Operating-Cash-Flow	15.53
	EV-to-EBIT	20.93
	EV-to-Forward-EBIT	23.33
	EV-to-EBITDA	17.27
	EV-to-Forward-EBITDA	16.7
	EV-to-Revenue	5.3
	EV-to-Forward-Revenue	4.78
	EV-to-FCF	17.87
	Price-to-GF-Value	0.66
	Price-to-Projected-FCF	2.65
	Price-to-Median-PS-Value	0.44
	Price-to-Peter-Lynch-Fair-Value	1.18
	Price-to-Graham-Number	3.5
	Price-to-Net-Current-Asset-Value	40.4
	Earnings Yield (Greenblatt) %	4.78
	FCF Yield %	5.38
	Forward Rate of Return (Yacktman) %	22.04

Financials (Next Earnings Date:2026-07-30 Est.)

Annual Quarterly TTM

MIL:1DXCM's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

DexCom Inc Executives

Details

GF Value™: €91.36

MIL:1DXCM

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 1DXCM. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	4,140.221
	EPS (TTM) (€)	2.008
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	42.39
	14-Day RSI	41.71
	14-Day ATR (€)	0.922345
	20-Day SMA (€)	63.71
	12-1 Month Momentum %	-15.32
	52-Week Range (€)	47.585 - 77.31
	Shares Outstanding (Mil)	385.87

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	9
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

DexCom Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

DexCom Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-30 16:30	In 121 days
Third quarter earnings results for 2026	2026-10-30	In 120 days
Second quarter earnings conference call for 2026	2026-07-30 16:30	In 29 days
Second quarter earnings results for 2026	2026-07-30	In 28 days
General meeting for 2026	2026-05-27 14:00	62.40 (+2.97%)
Investor Day	2026-05-14 13:15	51.60 (+0.00%)
First quarter earnings conference call for 2026	2026-04-30 16:30	51.60 (+0.00%)
First quarter earnings results for 2026	2026-04-30	51.60 (+0.00%)
47th Annual Raymond James Institutional Investors Conference	2026-03-02 13:05	62.69 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-12 16:30	58.45 (+0.00%)

Show

Entries

DexCom Inc Frequently Asked Questions

What is DexCom Inc(MIL:1DXCM)'s stock price today?

The current price of MIL:1DXCM is €60.60. The 52 week high of MIL:1DXCM is €77.31 and 52 week low is €47.59.

When is next earnings date of DexCom Inc(MIL:1DXCM)?

The next earnings date of DexCom Inc(MIL:1DXCM) is 2026-07-30 Est..

Does DexCom Inc(MIL:1DXCM) pay dividends? If so, how much?

DexCom Inc(MIL:1DXCM) does not pay dividend.

Press Release

	Subject	Date
	Dexcom Further Advances Vision of Glucose Biosensing for All	2026-06-23
	Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin	2026-06-06
	Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026	2026-06-04
	Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience	2026-06-02
	Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany	2026-05-18
	Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day	2026-05-14
	Dexcom Reports First Quarter 2026 Financial Results	2026-04-30
	Why Medtech Giants Are Quietly Paying Up for AI Diagnostics	2026-04-29
	Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?	2026-04-09
	Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time	2026-04-02

10/Page

Articles on DexCom Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.